Atlas Trials

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Clinical trial NCT02706626 · TERMINATED

Trial details

NCT number
NCT02706626
Sponsor
Criterium, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2017-03-09
Primary completion
2020-10-08
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.